Saundra Sturdy, APRN
Medical-Surgical · Tulsa, OKNPI 1538189527
Payments from drug & device makers
Across 451 payments — averaging $26.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Coloplast$1K
- Johnson & Johnson$848
- Astellas Pharma US Inc$736
- Sumitomo Pharma America, Inc.$586
- Medtronic$563
- plus $6K from 33 others
What the payments were for
- Consulting fees$1,32811%
- Travel & lodging$4624%
- Food & beverage$9,96384%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 21 | $2,595 |
| Coloplast | 32 | $1,022 |
| Johnson & Johnson | 35 | $848 |
| Astellas Pharma US Inc | 39 | $736 |
| Sumitomo Pharma America, Inc. | 39 | $586 |
| Medtronic | 6 | $563 |
| Dendreon Pharmaceuticals LLC | 21 | $549 |
| Bayer | 24 | $523 |
| Merck | 20 | $399 |
| Teleflex LLC | 17 | $290 |
| Hollister Incorporated | 5 | $286 |
| Endo Pharmaceuticals Inc. | 19 | $280 |
| Pfizer | 12 | $277 |
| Blue Earth Diagnostics | 13 | $265 |
| AbbVie(2 entities) | 37 | $263 |
| Sun Pharmaceutical Industries Inc. | 12 | $214 |
| Urovant Sciences Inc | 11 | $207 |
| Tolmar Pharmaceuticals, Inc. | 8 | $184 |
| Accord Healthcare, Inc. | 9 | $171 |
| Boston Scientific | 4 | $151 |
| Urogen Pharma, Inc. | 7 | $143 |
| Novartis | 5 | $142 |
| Myovant Sciences Inc. | 7 | $139 |
| AstraZeneca | 6 | $113 |
| Valencia Technologies Corporation | 5 | $109 |
| Progenics Pharmaceuticals, Inc. | 4 | $102 |
| Myriad Genetic Laboratories, Inc. | 3 | $101 |
| Olympus America Inc. | 4 | $95 |
| Amgen | 5 | $94 |
| Novo Nordisk | 4 | $83 |
| Endo USA, Inc. | 4 | $77 |
| Halozyme Inc | 3 | $56 |
| Tolmar, Inc. | 2 | $51 |
| 180 Medical, Inc. | 1 | $51 |
| Clovis Oncology, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $21 |
| Mission Pharmacal Company | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$2,123
- INTERSTIM$458
- Infyna Chic$137
- Luja Coude$135
- ALTIS$134
- SPEEDICATH$130
- rezum Generator$111
How this compares
Too few medical-surgical providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 41 | $35,104 |
| GemtesaVibegron | 25 | $15,999 |
| Estradiol | 81 | $6,054 |
| Solifenacin Succinate | 35 | $1,633 |
| Trospium Chloride | 22 | $1,258 |
| Tamsulosin Hcl | 21 | $336 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 37 | $209 |
| Cephalexin | 25 | $139 |
| Ciprofloxacin Hcl | 12 | $72 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 18 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $736 | $35,10441 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $586 | $15,99925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical-surgical providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other medical-surgical in Tulsa
- Kendra ThompsonOklahoma City$13
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.